SCHEMBL1673294

SCHEMBL1673294

O=c1cc(S)[nH]c(=O)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9220998 0.67 GPR84 (0.50)
SCHEMBL1774205 0.67
SCHEMBL3362001 0.67
SCHEMBL60308 0.67
SCHEMBL325682 0.67
SCHEMBL13918178 0.67
SCHEMBL189997 0.67
SCHEMBL8188652 0.67
SCHEMBL1896344 0.67
SCHEMBL317622 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117729917-A Combination therapy using AKR1C3 activating compounds and immune checkpoint inhibitors 深圳艾欣达伟医药科技有限公司 2024-03-19 CN claimed
CN-113293203-B RNA 4-mercaptouracil specific labeling method and application thereof 西安交通大学 2022-07-12 CN claimed
CN-114746753-A Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application 深圳艾欣达伟医药科技有限公司 2022-07-12 CN claimed
CN-114350770-A Double-function marking method of 4-mercaptouracil and application thereof in sequence enrichment and single base resolution sequencing 西安交通大学 2022-04-15 CN claimed
CN-113293203-A RNA 4-mercaptouracil specific labeling method and application thereof 西安交通大学 2021-08-24 CN claimed
CN-114728934-B Heterocyclic derivatives, pharmaceutical compositions and their use for treating or ameliorating cancer 托雷莫治疗股份公司 2024-08-27 CN disclosed
CN-118256453-A Scalable manufacturing method for producing recombinant lentiviral vectors in serum-free suspension cell culture systems 费城儿童医院 2024-06-28 CN disclosed
CN-118139642-A Compositions and methods for treating cancer 约翰·霍普金斯大学 2024-06-04 CN disclosed
CN-117729917-A Combination therapy using AKR1C3 activating compounds and immune checkpoint inhibitors 深圳艾欣达伟医药科技有限公司 2024-03-19 CN disclosed
CN-117715658-A Method for inhibiting RAS 锐新医药公司 2024-03-15 CN disclosed
CN-117683049-A Indole derivatives as RAS inhibitors for the treatment of cancer 锐新医药公司 2024-03-12 CN disclosed
CN-117616031-A RAS inhibitors for the treatment of cancer 锐新医药公司 2024-02-27 CN disclosed
WO-2014015291-A1 FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX ZHOU HAN-JIE (US) 2014-01-23 WO disclosed
US-20140024661-A1 FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 CLEAVE BIOSCIENCES, INC. (US) 2014-01-23 US disclosed
US-8309356-B2 Pseudocomplementary oligonucleotides for targeted gene therapy YALE UNIVERSITY (US) 2012-11-13 US disclosed
US-8124417-B2 Method for analyzing nucleobases on a single molecular basis JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2012-02-28 US disclosed
US-8124417-B2 Method for analyzing nucleobases on a single molecular basis JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2012-02-28 US disclosed
US-20110086905-A1 Pseudocomplementary Oligonucleotides for Targeted Gene Therapy YALE UNIVERSITY 2011-04-14 US disclosed
US-20090155917-A1 Method for analyzing nucleobases on a single molecular basis JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2009-06-18 US disclosed
US-20090155917-A1 Method for analyzing nucleobases on a single molecular basis JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2009-06-18 US disclosed